FrancophonIA/ELRC3.0 huggingface dataset:
English: The incidence of severe cases was similar for clopidogrel and ASA.
Maltese: L-inċidenza ta' każi severi kienet simili għal clopidogrel u għal ASA.
English: • This medicinal product must be administered under close medical supervision in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to risk of haemolysis (see section 4.8).
Maltese: • Dan il-prodott mediċinali jrid jingħata taħt superviżjoni medika stretta f'pazjenti b'defiċjenza ta' glucose-6-phosphate dehydrogenase (G6PD) minħabba r-riskju ta' emolisi (ara sezzjoni 4.8).
English: Contains lactose and Allura Red AC. See leaflet for further information.
Maltese: Allura Red AC jista' jikkawża reazzjonijiet allerġiċi.
English: BGP Products SRL Tel: +40 372 579 000
Maltese: BGP Products Switzerland GmbH Eesti filiaal Tel: + 372 6363 052
English: In CURE, CLARITY, ACTIVE-A and one of the cohort studies (Trenk), no increased event rate was observed based on metaboliser status.
Maltese: Fi CURE, CLARITY, ACTIVE-A u wieħed mill-istudji ko-orti (Trenk), ma ġiet osservata l-ebda żieda fir-rata ta' avvenimenti bbażata fuq l-istatus tal-metabolizzatur.
English: Ninety five patients (7%) in the guided de-escalation group and 118 patients (9%) in the control group (p non-inferiority=0.0004) had an event.
Maltese: Ħamsa u disgħin pazjent (7%) fil-grupp iggwidat ta' tnaqqis fil-qawwa u 118-il pazjent (9%) fil-grupp ta' kontroll (p mhux inferjuri = 0.0004) kellhom avveniment.
English: The patients were followed for 30 days.
Maltese: Il-pazjenti kienu segwiti għal 30 jum.
English: This leaflet was last revised in {MM/YYYY}
Maltese: Reazzjonijet inkroċjati fost thienopyridines
English: Posology Adults and elderly
Maltese: Adulti u anzjani
English: • methotrexate, a medicine used to treat severe joint disease (rheumatoid arthritis) or skin disease (psoriasis),
Maltese: • methotrexate, mediċina użati għat-trattament ta' mard sever fil-ġogi (artrite rewmatojde) jew mard fil-ġilda (psoriasis),
English: The elimination half-life of the main circulating (inactive) metabolite was 8 hours after single and repeated administration.
Maltese: Il-half-life tat-tneħħija tal-metabolit (inattiv) prinċipali ċirkolanti kien 8 sigħat wara amministrazzjoni waħda u ripetuta.
English: Published frequencies for the poor CYP2C19 metaboliser genotypes are approximately 2% for Caucasians, 4% for Blacks and 14% for Chinese.
Maltese: Skont kif ippubblikat, il-frekwenza ta' ġenotipi ta' metabolizzaturi dgħajfa ta' CYP2C19 huma madwar 2% għall-Kawkasi, 4% għas-Suwed u 14% għaċ-Ċiniżi.
English: Clopidogrel/Acetylsalicylic acid Mylan contains sodium This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodiumfree'.
Maltese: Clopidogrel/Acetylsalicylic acid Mylan fih sodium Din il-mediċina fiha anqas minn 1 mmol sodium (23 mg) f'kull pillola, jiġifieri essenzjalment ‘ħielsa mis-sodium'.
English: • Alcohol may increase the risk of gastrointestinal injury when taken with ASA.
Maltese: • L-alkoħol jista' jżid ir-riskju ta' ferita gastrointestinali meta jittieħed flimkien ma' ASA.
English: Patients were randomized to receive either prasugrel 5 or 10 mg/d (Days 0-14) (n=1306), or prasugrel 5 or 10 mg/d (Days 0-7) then de-escalated to clopidogrel 75 mg/d (Days 8-14) (n=1306), in combination with ASA (<100 mg/day).
Maltese: B'mod arbitrarju l-pazjenti ntgħażlu biex jirċievu jew prasugrel 5 jew 10 mg/ġ (Ġranet 0-14) (n=1306), jew prasugrel 5 jew 10 mg/ġ (Ġranet 0-7) fejn imbagħad ilqawwa tnaqqset għal clopidogrel 75 mg/ġ (Ġranet 8-14) (n=1306), flimkien ma' ASA (<100 mg/ġurnata).
English: Upper gastrointestinal disorders (oesophagitis, oesophageal ulceration, perforation, erosive gastritis, erosive duodenitis; gastroduodenal ulcer/perforations)*; lower gastrointestinal disorders (small [jejunum and ileum] and large [colon and rectum] intestinal ulcers, colitis and intestinal perforation)*; upper gastro-intestinal symptoms* such as gastralgia (see section 4.4); these ASA related GI reactions may or may not be associated with haemorrhage, and may occur at any dose of acetylsalicylic acid and in patients with or without warning symptoms or a previous history of serious GI events*.
Maltese: Disturbi gastro-intestinali tan-naħa ta' fuq talimsaren (esofaġite, ulċerazzjoni esofaġeali, perforazzjoni, gastrite erosiva, dwodenite erosiva, ulċera/perforazzjoni gastro-dwodenali) disturbi gastrointestinali tan-naħa t'isfel tal-imsaren (ulċeri tal-intestin iż-żgħir [ġeġunu u ilju] u l-kbir [kolon u rettu] kolite u perforazzjoni intestinali)
English: How to take Clopidogrel/Acetylsalicylic acid Mylan
Maltese: Tiħux Clopidogrel/Acetylsalicylic acid Mylan
English: The safety and efficacy of clopidogrel plus ASA have been evaluated in three double-blind studies involving over 61,900 patients: the CURE, CLARITY and COMMIT studies, comparing clopidogrel plus ASA to ASA alone, both treatments given in combination with other standard therapy.
Maltese: Is-sigurtà u l-effikaċja ta' clopidogrel u ASA ġew evalwati fi tliet studji double-blind li jinvolvu aktar minn 61,900 pazjent: u l-istudji CURE, CLARITY u COMMIT, li jqabblu clopidogrel u ASA ma' ASA waħdu, iż-żewġ trattamenti mogħtija flimkien ma' terapija standard oħra.
English: • In children under 18 years of age, there is a possible association between ASA and Reye's syndrome.
Maltese: • Fit-tfal taħt it-18-il sena, hemm il-possibiltà ta' relazzjoni bejn ASA u s-sindromu ta' Reye meta ASA jingħata lit-tfal.
English: Uricosurics (benzbromarone, probenecid, sulfinpyrazone) Caution is required because ASA may inhibit the effect of uricosuric agents through competitive elimination of uric acid.
Maltese: Urikosuriċi (benzbromarone, probenecid, sulfinpyrazone) Hemm bżonn ta' kawtela għax ASA jista' jinibixxi l-effetti tas-sustanzi urikosuriċi permezz taleliminazzjoni kompetitiva ta' aċidu uriku.
English: In addition, IPA was 32% (24 hours) and 61% (Day 5), which were greater than in the poor metabolisers receiving the 300 mg/75 mg regimen, and were similar to the other CYP2C19 metaboliser groups receiving the 300 mg/75 mg regimen.
Maltese: Barra minn hekk, IPA kienet ta' 32% (24 siegħa) u 61% (Jum 5), u dawn kienu akbar milli fil-metabolizzaturi dgħajfa li rċevew is-sistema ta' dożaġġ ta' 300 mg/75 mg u simili għall-gruppi ta' metabolizzaturi l-oħra ta' CYP2C19 li rċevew is-sistema ta' dożaġġ ta' 300 mg/75 mg.
English: Clopidogrel must be metabolised by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.
Maltese: Clopidogrel irid ikun metabolizzat mill-enzimi CYP450 sabiex jiġi prodott il-metabolit attiv li jinibixxi l-aggregazzjoni tal-plejtlits.
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets EU/1/19/1395/001 - Cartons of 28 film coated tablets in aluminium blister packs EU/1/19/1395/002 - Cartons of 30 film coated tablets in aluminium blister packs EU/1/19/1395/003 - Cartons of 28 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/004 - Cartons of 30 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/005 - Cartons of 100 film coated tablets in HDPE bottle packs
Maltese: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg pilloli miksija b'rita EU/1/19/1395/001 - Kartun li fih 28 pillola miksija b'rita f'pakketti bil-folji tal-aluminju EU/1/19/1395/002 - Kartun li fih 30 pillola miksija b'rita f'pakketti bil-folji tal-aluminju EU/1/19/1395/003 - Kartun li fih 28 × 1 (doża waħda) pillola miksija b'rita f'pakketti bil-folji talaluminju
English: Repeated doses of clopidogrel 75 mg per day produced substantial inhibition of ADP-induced platelet aggregation from the first day; this increased progressively and reached steady state between Day 3 and Day 7.
Maltese: Dożi repetuti ta' 75 mg kuljum ipproduċew inibizzjoni sostanzjali tal-aggregazzjoni tal-plejtlets indotti minn ADP mill-ewwel ġurnata; dan żied progressivament u laħaq livell fiss bejn Jum 3 u Jum 7.
English: The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
Maltese: Il-metabolit attiv ta' clopidogrel jinibixxi b'mod selettiv l-irbit ta' adenosine diphosphate (ADP) mar-riċettur P2Y12 tal-plejtlet, u l-attivazzjoni wara tal-kumpless glikoproteiniku GPIIb/IIIa permezz ta' ADP, u għalhekk l-aggregazzjoni tal-plejtlet tiġi inibita.
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets Pink, oval shaped, biconvex, film-coated tablets, approximately 14.8 mm x 7.8 mm debossed with “CA3” on one side of the tablet and “M” on the other side.
Maltese: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg pilloli miksija b'rita Pilloli miksija b'rita, roża, b'forma ovali, bikonvessi, b'daqs ta' madwar 14.8 mm × 7.8 mm imnaqqxa b'“CA3” fuq naħa waħda tal-pillola u “M” fuq in-naħa l-oħra.
English: Although the administration of clopidogrel 75 mg/day did not modify the pharmacokinetics of S-warfarin or International Normalised Ratio (INR) in patients receiving long-term warfarin therapy, coadministration of clopidogrel with warfarin increases the risk of bleeding because of independent effects on haemostasis.
Maltese: Għalkemm l-għoti ta' clopidogrel 75 mg/jum ma mmodifikax il-farmakokinetika ta' S-warfarin jew il-Proporzjon Normalizzat Internazzjonali (INR) f'pazjenti li rċevew terapija għat-tul ta' warfarin, l-għoti flimkien ta' clopidogrel ma' warfarin iżid ir-riskju ta' fsada minħabba effetti indipendenti fuq l-emostasi.
English: Reye's syndrome is a very rare disease which can be fatal.
Maltese: Is-sindromu ta' Reye hija marda rari ħafna li tista' tkun fatali.
English: This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free'
Maltese: Dan il-prodott mediċinali fih anqas minn 1 mmol sodium (23 mg) f'kull pillola, jiġifieri essenzjalment ‘ħieles mis-sodium'.
English: ASA group, a 20% relative risk reduction (RRR) (95% CI of 10%-28%; p=0.00009) for the clopidogrel plus ASA group [17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)].
Maltese: In-numru ta' pazjenti li għaddew mill-punt primarju ta' tmien [mewt kardjovaskulari (KV), infart mijokardijaku (IM) jew puplesija] kien 582 (9.3%) fil-grupp ikkurat bi clopidogrel flimkien ma' ASA u 719 (11.4%) fil-grupp ikkurat b'ASA, li jissarraf fi tnaqqis fir-riskju relattiv (TRR) ta' 20% (95% CI ta' 10% - 28%; p=0.00009) għall-grupp ikkurat bi clopidogrel flimkien ma' ASA [tnaqqis fir-riskju relattiv ta' 17% f'pazjenti li kienu kkurati b'mod konservattiv, 29% meta kellhom anġjoplastija koronarja transluminali perkutaneja (PTCA) bi stent jew mingħajru u 10% meta kellhom trapjant ta' bajpass f'arterja koronarja (CABG)].
English: • Third trimester of pregnancy (see section 4.6).
Maltese: • It-tielet trimestru tat-tqala (ara sezzjoni 4.6).
English: In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia).
Maltese: Partikularment, f'analiżi post-hoc f' 2,172 pazjent (17% tal-popolazzjoni kollha CURE) li kellhom stent impoġġija (Stent-CURE), id-data wriet li clopidogrel, imqabbel ma plaċebo, wera RRR sinifikanti ta' 26.
English: The primary endpoint (the combined incidence of CV death, MI, stroke and BARC bleeding grade ≥2 at 12 months) was met showing non-inferiority.
Maltese: Il-punt finali primarju (l-inċidenza meħuda kollha flimkien ta' mewt kardjovaskulari, MI, puplesija u fsada BARC ta' grad ≥2 wara 12-il xahar) intlaħaq u wera li ma kienx hemm inferjorità.
English: Switching from a more potent P2Y12 receptor inhibitor to clopidogrel in association with aspirin after acute phase in ACS has been evaluated in two randomized investigator-sponsored studies (ISS)TOPIC and TROPICAL-ACS - with clinical outcome data.
Maltese: Il-bidla minn inibitur aktar qawwi tar-riċettur P2Y12 għal clopidogrel flimkien mal-aspirina wara l-fażi akuta f'ACS ġiet evalwata f'żewġ studji mħallsin mill-investigutur u magħmula b'mod arbitrarju (ISS, investigator-sponsored studies) -TOPIC u TROPICAL-ACS - b'tagħrif dwar ir-riżultat kliniku.
English: The primary outcome, a composite of cardiovascular death, stroke, urgent revascularization, and BARC (Bleeding Academic Research Consortium) bleeding ≥2 at 1 year post ACS, occurred in 43 patients (13.4%) in the de-escalated DAPT group and in 85 patients (26.3%) in the unchanged DAPT group (p<0.01).
Maltese: Ir-riżultat primarju, taħlita ta' mewt kardjovaskulari, puplesija, vaskularazzjoni urġenti mill-ġdid u fsada BARC (Bleeding Academic Research Consortium) ≥2 f'sena wara ACS, seħħ f'43 pazjent (13.4%) fil-grupp DAPT ta' tnaqqis fil-qawwa u f'85 pazjent (26.
English: Other concomitant therapy with ASA Interactions with the following medicinal products have been reported with ASA:
Maltese: Terapija oħra meħuda flimkien ma' ASA Ġew irrapportati interazzjonijiet bejn ASA u l-prodotti mediċinali li ġejjin:
English: In patients concomitantly receiving nicorandil and NSAIDs including ASA and LAS, there is an increased risk for severe complications such as gastrointestinal ulceration, perforation and haemorrhage (see section 4.4).
Maltese: F'pazjenti li fl-istess ħin qegħdin jirċievu wkoll nicorandil u NSAIDs inklużi ASA u LAS, hemm żieda fir-riskju għal kumplikazzjonijiet serji bħal ulċerazzjoni gastrointestinali, perforazzjoni u emorraġija (ara sezzjoni 4.4).
English: EU/1/19/1395/001 - 28 film coated tablets in aluminium blister packs EU/1/19/1395/002 - 30 film coated tablets in aluminium blister packs EU/1/19/1395/003 - 28 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/004 - 30 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/005 - 100 film coated tablets in HDPE bottle packs
Maltese: EU/1/19/1395/001 - 28 pillola miksija b'rita f'pakketti bil-folji tal-aluminju EU/1/19/1395/002 - 30 pillola miksija b'rita f'pakketti bil-folji tal-aluminju EU/1/19/1395/003 - 28 × 1 (doża waħda) pillola miksija b'rita f'pakketti bil-folji tal-aluminju EU/1/19/1395/004 - 30 × 1 (doża waħda) pillola miksija b'rita f'pakketti bil-folji tal-aluminju EU/1/19/1395/005 - 100 pillola miksija b'rita f'pakketti bil-fliexken tal-HDPE
English: The 2x2 factorial design COMMIT trial included 45,852 patients presenting within 24 hours of the onset of the symptoms of suspected MI with supporting ECG abnormalities (i.e. ST elevation, ST
Maltese: L-għamla ta' 2×2 factorial tal-prova COMMIT inkludiet 45,852 pazjent li ppreżentaw fi żmien 24 siegħa mill-ħin li bdew is-sintomi ta' suspett ta' MI b'abnormalitajiet fl-ECG suġġestivi t'hekk (jiġifieri ST elevat, ST imniżżel jew blokk tal-bundle branch tax-xellug).
English: The incidence of clinically significant bleeding was similar to that observed when thrombolytic agents and heparin are co-administered with ASA (see section 4.8).
Maltese: L-inċidenza taddmija klinikament sinifikanti kienet simili għal dik osservata meta sustanzi trombolitiċi u eparina jingħataw flimkien ma' ASA (ara sezzjoni 4.8).
English: As a dual antiplatelet agent, Clopidogrel/Acetylsalicylic acid Mylan should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with other NSAIDs including Cox-2 inhibitors, heparin, glycoprotein IIb/IIIa inhibitors, selective serotonin reuptake inhibitors (SSRIs), thrombolytics, or other medicinal products associated with bleeding risk such as pentoxifylline (see section 4.5).
Maltese: Bħala sustanza li għandha azzjoni dupliċi kontra l-plejtlets, Clopidogrel/Acetylsalicylic acid Mylan għandu jintuża b'kawtela ma' pazjenti li jista' jkollhom riskju ta' iktar dmija minn trawma, operazzjoni jew kondizzjonijiet patoloġiċi oħra u pazjenti li jkunu qed jirċievu l-kura b'NSAIDs oħra li jinkludu l-inibituri ta' Cox-2, heparin jew inibituri ta' glycoprotein IIb/IIIa, jew inibituri selettivi tal-ġbir mill-ġdid ta' serotonin (SSRIs), jew prodotti mediċinali marbuta ma' riskju ta' fsada bħal pentoxifylline (ara sezzjoni 4.5).
English: Non-cardiogenic pulmonary edema can occur with acute and chronic acetylsalicylic acid overdose (see section 4.8).
Maltese: Edima pulmonarja li mhijiex kardjoġenika tista' sseħħ b'doża eċċessiva akuta u kronika ta' acetylsalicylic acid (ara sezzjoni 4.8).
English: Bleeding time prolonged, neutrophil count decreased, platelet count decreased * Information reported in published information for ASA with frequency “not known”.
Maltese: Informazzjoni rrappurtata f'informazzjoni ppubblikata għal ASA b'frekwenza “mhux magħrufa”.
English: TOPIC (Timing Of Platelet Inhibition after acute Coronary syndrome) This randomized, open-label trial included ACS patients requiring PCI.
Maltese: TOPIC (L-Aħjar Żmien għall-Inibizzjoni tal-Plejtlits wara sindromu Koronarju akut-Timing Of Platelet Inhibition after acute Coronary syndrome) Din il-prova open-label u magħmula b'mod arbitrarju kienet tinkludi pazjenti ACS li kellhom bżonn ta' PCI.
English: From the beginning of the sixth month of pregnancy, all prostaglandin synthesis inhibitors may expose: the foetus to: cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligo-hydroamniosis;
Maltese: • il-fetu għal: - tossiċità kardjopulmonarja (għeluq prematur tad-ductus arteriosus u ipertensjoni pulmonarja); - disfunzjoni renali li tista' twassal għall-insuffiċjenza renali b'oligo-idroamnjożi;
English: Following toxic doses (10-20 g), the plasma half-life may be increased to over 20 hours.
Maltese: Wara dożi tossiċi (1020 g), il-half-life fil-plażma jista' jiżdied għal iktar minn 20 siegħa.
English: • acetazolamide, a medicine used to treat glaucoma (increased ocular pressure) or epilepsy or to increase urine flow,
Maltese: • acetazolamide, mediċina użata għat-trattament tal-glawkoma (żieda fil-pressjoni okulari) jew tal-epilessija jew biex iżżid il-fluss tal-awrina,
English: No substantial differences in active metabolite exposure and mean inhibition of platelet aggregation (IPA) were observed between ultra-rapid, extensive and intermediate metabolisers.
Maltese: Ma ġew osservati l-ebda differenzi sostanzjali fl-espożizzjoni tal-metabolit attiv u l-inibizzjoni medja tal-aggregazzjoni tal-plejtlits (IPA) bejn metabolizzaturi estremament mgħaġġla, estensivi u intermedji.
English: EU/1/19/1395/006 - 28 film coated tablets in aluminium blister packs EU/1/19/1395/007 - 30 film coated tablets in aluminium blister packs EU/1/19/1395/008 - 28 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/009 - 30 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/010 - 100 film coated tablets in HDPE bottle packs
Maltese: EU/1/19/1395/006 - 28 pillola miksija b'rita f'pakketti bil-folji tal-aluminju EU/1/19/1395/007 - 30 pillola miksija b'rita f'pakketti bil-folji tal-aluminju EU/1/19/1395/008 - 28 × 1 (doża waħda) pillola miksija b'rita f'pakketti bil-folji tal-aluminju EU/1/19/1395/009 - 30 × 1 (doża waħda) pillola miksija b'rita f'pakketti bil-folji tal-aluminju EU/1/19/1395/010 - 100 pillola miksija b'rita f'pakketti bil-fliexken tal-HDPE
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets Yellow, oval shaped, biconvex, film-coated tablets, approximately 14.5 mm x 7.4 mm debossed with “CA2” on one side of the tablet and “M” on the other side.
Maltese: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg pilloli miksija b'rita Pilloli miksija b'rita, sofor, b'forma ovali, bikonvessi, b'daqs ta' madwar 14.5 mm × 7.4 mm imnaqqxa b'“CA2” fuq naħa waħda tal-pillola u “M” fuq in-naħa l-oħra.
English: In poor metabolisers, active metabolite exposure was decreased by 63-71% compared to extensive metabolisers.
Maltese: Fil-metabolizzaturi dgħajfa, l-espożizzjoni tal-metabolit attiv tnaqqset b'63 - 71% meta mqabbla ma' metabolizzaturi estensivi.
English: Following absorption, the ASA in Clopidogrel/Acetylsalicylic acid Mylan is hydrolysed to salicylic acid with peak plasma levels of salicylic acid occurring within 1 hour of dosing, such that plasma levels of ASA are essentially undetectable 1.5-3 hours after dosing.
Maltese: Wara li jiġi assorbit, l-ASA f'Clopidogrel/Acetylsalicylic acid Mylan jiġi idrolizzat għal salicylic acid bl-ogħla livelli ta' salicylic acid fil-plażma jintlaħqu fi żmien siegħa minn wara li tittieħed id-doża, waqt li ftit li xejn ma ssib livelli ta' ASA fil-plażma wara 1.5 - 3 sigħat mid-doża.
English: Clopidogrel/Acetylsalicylic acid Mylan is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA).
Maltese: Clopidogrel/Acetylsalicylic acid Mylan huwa indikat għall-prevenzjoni sekondarja ta' avvenimenti aterotrombotiċi f'pazjenti adulti li diġà qegħdin jieħdu kemm clopidogrel u kemm acetylsalicylic acid (ASA).
English: Activated charcoal (adsorbent) and sodium sulphate (laxative) are then administered.
Maltese: Jiġu mbagħad mogħtija charcoal attivat (adsorbent) u sodium sulphate (lassativ).
English: Kounis syndrome (vasospastic allergic angina / allergic myocardial infarction) in the context of a hypersensitivity reaction due to acetylsalicylic acid* or clopidogrel**
Maltese: Sindrome ta' Kounis (anġina allerġika vasospastika / infart mijokardijaku allerġiku) f'kuntest ta' reazzjoni ta' sensittività eċċessiva għal acetylsalicylic acid jew clopidogrel
English: Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), bone marrow failure*, aplastic anaemia, pancytopenia, bicytopenia*, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia, haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency* (see section
Maltese: *, anemija aplastika, panċitopenija, biċitopenija agranuloċitosi tromboċitotopenija severa, emofilja A akwiżita, granuloċitopenija, anemija, anemija emolitika f'pazjenti b'insuffiċjenza ta' glucose-6-phosphate dehydrogenase (G6PD) (ara sezzjoni 4.4).
English: Jaundice (yellowing of skin and/or eyes); burning in stomach and/or oesophagus (gullet); severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions (for example, overall sensation of heat with sudden general discomfort until fainting); swelling in the mouth; blisters of the skin; skin allergy; sore mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain; changes in taste or loss of taste of foods, inflammation of small vessels.
Maltese: Suffejra (il-ġilda u/jew l-għajnejn jisfaru); ħruq fl-istonku u/jew fl-esofagu (gerżuma tal-ikel); uġigħ addominali sever flimkien ma' jew mingħajr uġigħ fid-dahar; deni, diffikultajiet biex tieħu n-nifs, xi daqqiet assoċjati mas-sogħla; reazzjonijiet allerġiċi ġeneralizzati (pereżempju, sensazzjoni ta' sħana ma' ġismek kollu b'skonfort ġenerali f'daqqa sakemm tħossok ħażin); nefħa fil-ħalq; infafet fil-ġilda; allerġija tal-ġilda; uġigħ fil-ħalq (stomatite); tnaqqis fil-pressjoni tad-demm; konfużjoni; alluċinazzjonijiet; uġigħ fil-ġogi; uġigħ muskolari; tibdil fil-mod ta' kif jintiegħem l-ikel jew ma tibqax ittiegħem l-ikel, infjammazzjoni tal-arterji u l-vini ż-żgħar.
English: Cases of Reye's syndrome have occurred following the use of salicylates during varicella infections (see section 4.4).
Maltese: Seħħew każijiet ta' sindromu ta' Reye wara l-użu ta' salicylates waqt infezzjonijiet bil-varicella (ara sezzjoni 4.4).